Wednesday, February 10, 2010, 2:23PM AEST - The Australian Stockmarket closes in 1 hour and 42 minutes.
To create a watchlist or portfolio of shares, Register

Neurocrine Biosciences Inc. (NBIX)

8:00AM AEST: 2.37 USD  Up 0.01 (0.42%)  
 MORE ON NBIX 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Neurocrine Biosciences, Inc. (NasdaqNM:NBIX) Delayed quote dataEdit
Last Trade:2.37 USD
Trade Time: 8:00AM AEST
Change:Up 0.01 (0.42%)
Prev Close:2.36
Open:2.39
Bid:1.48 x 100
Ask:3.32 x 100
1y Target Est:4.50
Day's Range:2.34 - 2.41
52wk Range:1.94 - 4.25
Volume:68,616
Avg Vol (3m):188,943
Market Cap:92.92M
P/E (ttm):N/A
EPS (ttm):-1.85
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add NBIX to Portfolio   Download Data

 HEADLINES 
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of I
EDGAR Online (Wed 6:17AM)
Neurocrine names CEO of Receptos to its board
AP (Tue 6:30AM)
Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
PR Newswire (Mon, Feb 8)
New Star Analyst Rankings for Neurocrine Biosciences, Inc.
StarMine (Fri, Feb 5)
Neurocrine Biosciences Inc. Q4 2009 Earnings Call Transcript
at Seeking Alpha (Thu, Feb 4)
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Thu, Feb 4)
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2009 Results
PR Newswire (Thu, Feb 4)
Q4 2009 Neurocrine Biosciences, Inc. Earnings Release - After Market Close
CCBN (Wed, Feb 3)
Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
PR Newswire (Thu, Jan 28)
Neurocrine Advances VMAT2 Inhibitor Program
PR Newswire (Tue, Dec 22)
More Headlines for NBIX...

 ANALYST 
EPS Est (next year) (Dec-09) :-1.39
EPS Est (in 2 years) (Dec-10) :-0.86
Avg Rec (current)*:2.7
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices